Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | CCL2 | P13500 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12240951 | 1.00 | MKNK2 (0.33) | MKNK2MKNK1BRD4CCL2HDAC8 | |
| SCHEMBL8179929 | 0.82 | TNKS2 (0.42) | MKNK2MKNK1BRD4HDAC8PIM1 | |
| SCHEMBL12219904 | 0.82 | TNKS2 (0.42) | MKNK2MKNK1BRD4HDAC8PIM1 | |
| SCHEMBL8164259 | 0.82 | TNKS2 (0.42) | MKNK2MKNK1BRD4HDAC8PIM1 | |
| SCHEMBL23997233 | 0.76 | ALDH1A1 (0.43) | MKNK2MKNK1BRD4PIM1PIM2 | |
| SCHEMBL8157312 | 0.73 | CNR1 (0.43) | MKNK2MKNK1 | |
| SCHEMBL12240953 | 0.73 | KDM4E (0.44) | MKNK2MKNK1TNKS2ALDH1A1CYP1A2 | |
| SCHEMBL12241449 | 0.73 | KDM4E (0.44) | MKNK2MKNK1TNKS2ALDH1A1CYP1A2 | |
| SCHEMBL12241460 | 0.73 | KDM4E (0.44) | MKNK2MKNK1TNKS2ALDH1A1CYP1A2 | |
| SCHEMBL18878150 | 0.71 | ACHE (0.42) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | MKNK2 4173/4885MKNK1 4548/4885BRD4 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.